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Introduction
TYK2 is a member of JAK family of receptor-associated tyrosine kinases. Upon binding of cytokines or growth factors to their receptor complexes, JAKs undergo auto-and trans-phosphorylation and phosphorylate the signal transducing receptor chain(s), which then provide docking sites for signal transducers and activators of transcription (STATs). STATs translocate to the nucleus and initiate transcription to induce ligand specific cellular responses. Activation of TYK2 occurs upon binding of several different cytokines, such as type I and type III interferons (IFNs), interleukin (IL-) 10, IL-12, IL-22, IL-23 and cytokines utilizing the gp130 receptor chain. 1 The most prominent immunological alterations observed in gene-targeted TYK2-deficient mice [2] [3] [4] and a naturally occurring TYK2 mutant mouse strain 5 are high susceptibility to microbial infections, resistance to several inflammatory and autoimmune diseases and impaired tumor immune surveillance. 1, 6 Breast cancer, thymoma and colon adenocarcinoma transplants grow more progressively in Tyk2 ¡/¡ mice. [7] [8] [9] Similarly, TYK2 deficiency results in a higher incidence of Abelson-induced leukemia, which was attributed to an impaired NK cell cytotoxicity and NK cell-mediated tumor immune surveillance. 10, 11 Impaired NK cell functions in the absence of TYK2 are not restricted to antitumor responses but were also observed in the context of Leishmania major infections. 12 To date, two TYK2-deficient patients have been reported who suffer from high susceptibility to infections among other immunological defects. 13, 14 The first TYK2 specific inhibitors have been recently developed and are considered as promising therapeutic agents for the treatment of inflammatory and autoimmune diseases. [15] [16] [17] [18] [19] [20] Very recently, tumor cell-intrinsic TYK2 activity has been linked to the development of T cell acute lymphoblastic leukemia (T-ALL) and cutaneous T cell lymphoma development in humans. 21, 22 Therefore, specific inhibition of TYK2 activity might be considered as a new therapeutic opportunity for some hematologic malignancies. Furthermore, invasiveness of certain types of prostate and breast cancer could be blocked by TYK2 inhibition in vitro. 23, 24 It becomes increasingly evident that, besides their canonical function, JAKs also exert functions independent of their catalytic activity and/or cytokine receptor association. Kinase-independent functions of human TYK2 were reported for IFNAR, IL-6R and IL-10R signaling complexes. [25] [26] [27] In murine cells, catalytically inactive TYK2 facilitates mitochondrial respiration and mediates crosstalk from the type I IFN receptor complex to the phosphoinositide 3-kinase (PI3K) pathway. 28, 29 Interestingly, nuclear translocation and chromatin association of TYK2 has been reported, however, the significance of this observation remains to be elucidated. 30 Thus, before blocking TYK2 in therapy it is of great importance to assess its kinase-independent functions in vivo.
Using gene-targeted mice that harbor a point mutation in the ATP-binding pocket of the TYK2 kinase domain (Tyk2 K923E ) we have recently reported that TYK2 kinase activity is essential for type I IFN signaling as well as antiviral responses in vivo. 31 In this study, we further investigated the role of TYK2 in NK cells and tumor immune surveillance and present the first evidence for kinase-independent functions of TYK2 in vivo.
Results
NK cells in the bone marrow develop normally in the absence of TYK2 or in the presence of kinase-inactive TYK2 NK cells develop in the bone marrow before migrating to the periphery where they undergo full maturation. 32 They develop from NK precursors (NKPs:
We found similar frequencies of total NK cells (Lin ¡ CD122 C ) (Fig. 1A) and of all three developmental stages in the bone marrow of WT, Tyk2 K923E and Tyk2 ¡/¡ mice (Fig. 1B) .
NK cell maturation depends on the presence of TYK2 and is partially restored by kinase-inactive TYK2
Next, we analyzed the frequency and maturation of splenic NK cells. The percentage of CD3e ¡ NK1.1 C NK cells was not differing from the WT (Fig. 1C) but their maturation was severely impaired in TYK2-deficient mice (Fig. 1D) . Compared to WT, NK cells from Tyk2 ¡/¡ mice showed a lower percentage of the most mature (CD27 ¡ CD11b C ) and a higher percentage of the least mature (CD27 ¡ CD11b ¡ ) NK cell population (Fig. 1D) . Surprisingly, this defect was partially restored in NK cells expressing TYK2 K923E (Fig. 1D) . In line with this, we found an intermediate abundance of NK cells positive for the late maturation marker KLRG1 in Tyk2 K923E between WT and Tyk2 ¡/¡ NK cells (Fig. 1E) . Although less pronounced, this also applied for the expression levels of KLRG1 (Fig. 1F) . These results establish a novel function of TYK2 in driving NK cell maturation, which is partially independent of its kinase activity.
Liver NK cell development depends on TYK2 kinase activity Liver-resident NK cells develop from a distinct lineage than conventional NK cells which are found in the spleen and circulate around the body. 33 Liver-resident and conventional NK cells are distinguished by their exclusive expression of CD49a and CD49b (DX5). 34 The percentage of NK cells among liver lymphocytes was not affected by the absence of TYK2 or its kinase activity (Fig. 1G) . However, we observed a strong reduction in the abundance of liver-resident NK cells (CD3e
mice, whereas the number of conventional NK cells was similar in all three genotypes (CD3e
NK cell receptor expression is differentially affected by the absence of TYK2 or the presence of kinase-inactive TYK2 NK cell activity is controlled by the integration of signals derived from activating and inhibitory receptors. 35 We did not detect any differences in the expression of the activating receptor Ly49H ( Fig. 2A) and NKp46 (Fig. S1A ) but we found fewer Tyk2 ¡/¡ than WT NK cells that express the inhibitory receptor Ly49G2 (Fig. 2B ) and the activating receptor NKG2D (Fig. 2C) . In contrast, Tyk2 K923E NK cells showed similar frequencies of Ly49G2
C and NKG2D C cells as WT NK cells, although expression levels were slightly reduced ( Fig. 2B and C) . Surprisingly, the abundance of DNAM-1 C NK cells was even higher in Tyk2 K923E than in WT mice, although the absence of TYK2 did not have any effect (Fig. 2D) . Thus, expression of TYK2 K923E not only restores some of the defects of Tyk2 ¡/¡ but also has consequences that differ from both, WT and Tyk2
Absence of TYK2 and presence of kinase-inactive TYK2 have distinct effects on the expression of miRNAs and mRNAs but not on the abundance of cytolytic proteins
As it becomes increasingly evident that miRNAs regulate NK cell activity, 36 we determined the expression levels of selected miRNAs in WT, Tyk2 K923E and Tyk2 ¡/¡ cells. In general, the differences were rather subtle and the miRNA expression patterns differed between naive (Fig. 3A) and IL-2-activated NK cells (Fig. 3B) . miR-155 expression was not significantly different in NK cells ex vivo (Fig. 3A) but it was increased in IL-2-expanded
Tyk2
K923E NK cells (Fig. 3B) . miR-233 was increased in Tyk2 K923E NK cells ex vivo (Fig. 3A) but decreased in Tyk2 K923E and Tyk2 ¡/¡ expanded NK cells (Fig. 3B) . miR-27a* showed reduced expression only in the absence of TYK2 in ex vivo NK cells, whereas we did not detect differences in miR-30e expression (Fig. 3A and B) .
We next analyzed the transcriptome of IL-2-expanded WT, Tyk2 K923E and Tyk2
¡/ ¡ NK cells using microarray technology.
We found very few differences between the genotypes: 27 transcripts were differentially expressed between Tyk2 ¡/¡ and WT or Tyk2 K923E and WT cells ( 2-fold change, P 0.05; Table S1 ). Among these transcripts, 11 differed at least 2-fold (P 0.05) between Tyk2 ¡/¡ and Tyk2 K923E NK cells (Table S1 ). Hierarchical cluster analysis of all genes (Fig. S2) confirmed that Tyk2 K923E differ from both Tyk2 ¡/¡ and WT NK cells.
IL-2 expansion of NK cells leads to a post-transcriptional upregulation of the cytolytic proteins granzyme B (GzmB) and perforin (Prf1). 37 Neither the absence of TYK2 nor the presence of TYK2 K923E had an effect on the expression of GzmB and Prf1 (Fig. 3C ).
IFNg production is dependent on TYK2 kinase activity IFNg is one of the main NK cell effector molecules. 38 Consistent with previous reports, 10, 12 we found strongly reduced STAT3 and STAT4 activation and impaired production of IFNg in the absence of TYK2 in response to IL-12 ( Fig. 4A) . TYK2 is not acting as a receptor scaffolding protein as we found similar surface expression of IL-12 receptor b1 (IL12Rb1) in all three genotypes (Fig. S1D) . JAK2 phosphorylation was strongly decreased in IL-12 stimulated Tyk2 K923E and Tyk2 ¡/¡ cells (Fig. 4A) , suggesting that the presence of enzymatically active TYK2 is required for full activation of JAK2.
Surprisingly, also NK1.1 and Ly49D receptor stimulation induced considerably lower IFNg production in Tyk2 K923E and Tyk2 ¡/¡ NK cells ( Fig. 4B and Fig. S3A ). It is important to note that NK1.1 and Ly49D receptor expression was not different between WT, Tyk2 K923E and Tyk2 ¡/¡ NK cells ( Fig. S1B and C) . Thus, the requirement for kinase-active TYK2 for IFNg production extends to NK cell receptor activation and is not limited to its function in the IL-12 signaling cascade.
To assess if Tyk2 K923E and Tyk2 ¡/¡ NK cells show generally impaired responses to receptor stimulation we analyzed the production of CCL3. 39 The percentage of CCL3 C cells after anti-NK1.1 antibody cross-linking was similarly reduced in Tyk2 K923E and Tyk2 ¡/¡ NK cells ( Fig. 4C left panel) . However, Tyk2
K923E
showed slightly higher expression levels than Tyk2 ¡/¡ cells ( Fig. 4C right panel cells was also observed after cross-linking with anti-Ly49D antibody (Fig. S3B ).
Kinase-inactive TYK2 partially restores cytotoxic capacity of NK cells
To further investigate how TYK2 and its kinase activity influence effector functions of NK cells, we assessed the ability of NK cells to form conjugates with target cells and to lyse them. We did not observe any differences in the formation of conjugates with YAC-1 target cells between WT, Tyk2 K923E and Tyk2 ¡/¡ NK cells (Fig. 5A) . Similarly, expression of the degranulation marker CD107a following NK1.1 or Ly49D receptor stimulation was not influenced by the absence of TYK2 or the presence of TYK2 K923E ( Fig. 5B and Fig. S3C ). In line with previous studies, 11 cytotoxicity of NK cells against a range of target cells in vitro was severely impaired in the absence of TYK2 (Fig. 5C-E) . However, Tyk2 K923E NK cells were able to lyse RMA-S, RMA-Rae1 and YAC-1 cells more efficiently than Tyk2 ¡/¡ , albeit not to the level reached by WT cells (Fig. 5C-E) . To determine cytotoxic activity in an in vivo setting, we intravenously injected cells that are deficient for MHC class I molecules (b2m ¡/¡ splenocytes) into WT, Tyk2
¡/¡ and Tyk2 K923E mice and determined their rejection. Consistent with our in vitro assays, Tyk2 K923E mice killed b2m ¡/¡ cells significantly better than Tyk2 ¡/¡ mice (Fig. 5F) . However, the difference between Tyk2 K923E and Tyk2 ¡/ ¡ mice appeared less pronounced than in vitro, suggesting that the cytotoxic capacity of Tyk2 K923E NK cells may depend on the type of target cell and/or environmental factors.
Kinase-inactive TYK2 mediates NK cell-dependent tumor surveillance
We next tested whether Tyk2 K923E NK cells are able to mediate tumor surveillance in vivo using two different NK cell-targeted tumor transplant models. Tyk2 K923E mice controlled the growth of RMA-S tumors similarly well as WT mice, whereas Tyk2 ¡/¡ mice developed significantly bigger tumors (Fig. 6A) . RMA-Rae1 tumors were again better controlled in Tyk2 K923E than in Tyk2 ¡/¡ mice, although not as efficiently as in WT mice (Fig. 6B) . Differences in tumor surveillance may also be due to differences in migratory or proliferative capacity of NK cells, and thus we determined the number of infiltrating NK cells in RMARae1 tumors. We found similar amounts of tumor-infiltrating NK cells in Tyk2 ¡/¡ and Tyk2 K923E mice, with respect to both the percentage (Fig. 6C , left panel) and the absolute numbers (Fig. 6C, right panel) . Taken together, our results clearly show that kinase-independent functions of TYK2 in NK cells are of physiological relevance.
Discussion
In this study we uncovered a key contribution of kinase-inactive TYK2 to NK cell-dependent tumor surveillance, thereby providing the first evidence for kinase-independent functions of TYK2 in vivo.
Previously we have shown that Tyk2 ¡/¡ mice develop B lymphoid tumors with shorter latency and higher incidence than WT mice. This phenotype was attributable to decreased NK cell cytotoxicity and tumor surveillance, although the underlying mechanisms remained unclear. 11 Herein we show that NK cells develop normally in the bone marrow regardless of the absence of TYK2 or presence of a kinase-inactive TYK2. Splenic NK cell maturation, however, is impaired in Tyk2 ¡/¡ but partially restored in Tyk2 K923E mice. The decrease in the most mature NK cell popu- We furthermore provide evidence for an involvement of TYK2 in the development of liver-resident NK cells. In contrast to the maturation of splenic NK cells, this fully depends on the presence of kinase-active TYK2. Liver-resident NK cells have just recently been discovered as an NK cell lineage distinct from conventional and other tissue resident NK cells. 33 It is unclear, how TYK2 impacts on their abundance in the liver. Type I IFN is likely not involved as normal numbers of liver-resident NK cells were reported in Ifnar1 ¡/¡ mice. 42 In contrast to Tyk2 K923E and Tyk2 ¡/¡ mice, a dramatic decrease of total liver NK cells was found in Ifng ¡/¡ mice, but this study did not differentiate NK cell subpopulations. 45 With respect to NK cell function, we demonstrate that TYK2 K923E partially restores cytotoxic activity of conventional NK cells against a range of different target cells. It seems likely that the role of TYK2 is linked to its role in IFNa/b signaling, as NK cells from both Ifnar1 ¡/¡ and Stat1 ¡/¡ mice have impaired killing activity. [40] [41] [42] 44 Effects on the expression of the lytic proteins GzmB and Prf1 and on degranulation could be excluded as the underlying mechanisms for IFNAR1 40 and TYK2. Furthermore, we show that TYK2 is not required for conjugate formation of NK cells with their target cells. In line with this, GzmB and Prf1 expression were not altered in the absence of STAT1. 41 Similar to our earlier findings for IFNa/b 31 , we did not observe differences between Tyk2 ¡/¡ and Tyk2 K923E NK cells in canonical IL-12 signaling: STAT3 and STAT4 activation and IFNg production are severely impaired in both genotypes. We demonstrate that the requirement for TYK2 in the IL-12 signaling cascade is not due to an IL-12Rb1 scaffolding function. Instead, TYK2 is needed for full activation of JAK2. This function was not reconstituted by TYK2 K923E , suggesting that TYK2-JAK2 cross-phosphorylation amplifies IL-12 responses in a similar manner as shown for JAK1 and JAK3 at the IL-2 receptor. 46 However, more detailed analyses including JAK2 mutants and specific inhibitors will be needed to define the exact interplay between TYK2 and JAK2 within the IL-12 receptor complex.
Moreover, we establish that enzymatically active TYK2 is required for IFNg production upon NK1.1 and Ly49D receptor stimulation. This is surprising, as TYK2 is not directly involved in signaling by NK cell activating receptors. 35 This finding cannot be correlated to a lower abundance of the most potent IFNg producing CD27
C CD11b C NK cell population, 47, 48 as the frequency of this population was unaffected by the loss of TYK2 or the presence of TYK2 K923E . In light of a recent study with human NK cells, one may speculate that epigenetic remodeling of the Ifng locus might be dependent on kinase-active TYK2. 49 However, we also found reduced induction of CCL3 in Tyk2
and Tyk2 K923E cells, indicating that TYK2 affects NK activating receptor signaling more globally.
NK cell function is also controlled by the integration of signals derived from activating and inhibitory receptors and by miRNAs. 35, 36 We found lower expression of the NK cell activating receptor NKGD2 in Tyk2 ¡/¡ NK cells. Expression of NKG2D in splenic NK cells from na€ ıve mice is regulated in a STAT3-dependent, STAT1-and IFNAR1-independent manner, 40, 50 suggesting a link between TYK2 and STAT3 functions. However, TYK2 deficiency did not recapitulate the increased expression of DNAM-1, GZMB and PRF1 reported in STAT3-deficient NK cells, 51 arguing against a general impairment of STAT3 activity in the absence of TYK2. Interestingly, expression of TYK2 K923E restores NKG2D expression but results in increased expression of DNAM-1. A similar "gain-of-function" phenotype as for DNAM-1 was observed for the expression of miR-223 in naive and miR-155 in IL-2 expanded Tyk2 K923E NK cells. The differences in miRNA expression patterns between ex vivo and IL-2 cultivated NK cells may be explained by autocrine/ paracrine actions of cytokines during the IL-2 culture, which may depend on TYK2 and regulate miR-155 and miR-233. [52] [53] [54] While it has been shown that miR-233 has a redundant role in regulation of NK cell effector functions, 36 miR-155 overexpression results in increased IFNg production and cytotoxicity. 47 ,52,53 Although we found IFNg production unaffected, miR-155 upregulation might contribute to the improved killing activity of Tyk2 K923E NK cells. Partial restoration of NK cell cytotoxicity by kinase-inactive TYK2 also translates into NK cell-mediated tumor surveillance. Using two different NK cell-targeted tumor cell lines, we could show that tumor surveillance in Tyk2 K923E is clearly better than in Tyk2 ¡/¡ mice. NK cell infiltration was similar in WT, Tyk2 K923E and Tyk2 ¡/¡ mice, indicating that indeed functional differences account for the differences in tumor control.
Interestingly, surveillance of RMA-S tumors even reached WT levels in Tyk2 K923E mice. Tumor cell-specificity may be explained by the differential expression of NK cell receptors. For example, DNAM-1 is particularly important for NK cellmediated killing when NKG2D ligands are not present on tumor cells. 55, 56 Besides, tumor cell-specificity could also be due to differences in the tumor environment as other cell types, such as myeloid cells, dendritic cells or stromal fibroblasts, may crucially contribute to tumor surveillance. The slightly increased production of CCL3 by Tyk2 K923E compared to Tyk2 ¡/¡ NK cells may also contribute to an improved tumor surveillance, for instance by enhancing the recruitment and activation of dendritic cells. In summary, we provide evidence that NK cell-dependent tumor surveillance does not strictly depend on the presence of kinase-active TYK2. This finding is of clinical relevance as there is growing interest in the use of TYK2 inhibitors for cancer therapy. 6, 21, 22 Nevertheless, kinase-inactive TYK2 does not fully reconstitute the WT situation and it is thus necessary to carefully consider the beneficial effects of TYK2 inhibitors versus their potential harmful effects on antitumor immunity. RMA-S 60 and RMA-Rae1 61 were cultured in RPMI1640 complete medium: RPMI1640 supplemented with L-glutamine (PAA), 10% heat-inactivated FCS (Invitrogen), 50 mM 2-mercaptoethanol (Gibco), 100 U/mL penicillin and 100 mg/ mL streptomycin (Sigma).
Materials and methods

Mice and cell lines
Tumor transplant experiments
Right and left flanks of WT, Tyk2 K923E and Tyk2 ¡/¡ animals were depilated 3 to 4 d prior to tumor cell injection. 10 6 RMA-S or RMA-Rae1 cells were injected subcutaneously into each flank and tumor growth was monitored every other day. After 11 (RMA-Rae1) or 15 (RMA-S) d, the body and tumor weight were assessed. For flow cytometry analysis of tumor infiltrating cells, tumors were pressed twice through 100 mm cell strainers to obtain a single cell suspension.
NK cell isolation, expansion and stimulation
Spleens were isolated and single cell suspensions were prepared by pressing through 100 mm cell strainers. NK cells were isolated using DX5-labeled MACS Ò beads according to the manufacturer's protocol (Miltenyi Biotec) and expanded in RPMI1640 complete medium supplemented with 5,000 U/ mL recombinant human IL-2 (Proleukin Ò , Novartis) for 5-7 d. Purity of NK cells was assessed by flow cytometry and were routinely 85-95% CD3e ¡ NK1.1 C of total cells. Cultivated NK cells were further stimulated with 5 ng/ mL recombinant mouse IL-12 (R&D Systems) for the times indicated and cells were used for Western blot analysis and supernatants for ELISA. For the analysis of the expression of G zmB, Prf1 and miRNAs, cells were deprived from IL-2 for 4 h prior to cell lysis.
Antibodies and flow cytometry
Single cell suspensions were prepared from spleen, bone marrow or liver. Liver lymphocytes were isolated by liver perfusion via the portal vein with 5-10 mL sterile PBS. Separation of lymphocytes and hepatocytes was performed using 37.5% percoll (GE Healthcare). CD16/CD32 (93), CD122 (TM-b1), CD49b (DX5), NK1.1 (PK136), NKp46 (29A1.4), CD3e (145-2C11), KLRG1 (2F1), CD27 (LG.7F9), CD11b (M1/70), Ly49H (3D10), Ly49G2 (4D11), NKG2D (CX5), DNAM-1 (10E5), IFNg (XMG1.2), CD107a (1D4B), NKp46 (29A1.4) and CCL3 (DNT3CC) were purchased from eBioscience. Mouse lineage antibodies (CD3: 145-2C11, CD19: 1D3, Ly6-C and Expression levels of miR-155, miR-223, miR-27a* and miR-30e were analyzed using RT-qPCR. Mean § SEM of two (A, n D 6¡8 per genotype) or three (B, n D 9¡11 per genotype) independent experiments is presented (*P < 0.05, ** P < 0.01, *** P < 0.001). (C) Protein levels of GzmB and Prf1 were analyzed by Western blot and quantified using ImageJ software. One representative blot and the mean values § SEM of the quantifications (normalized to WT cells) derived from two independent experiments are shown (n D 4 per genotype).
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Ly6G: RB6-8C5, Ter-119: TER119), Ly49D (4E5), CD49a (Ha31/8), TCR-b (H57-597) and IL-12Rb1 (114) were purchased from BD Biosciences. Analyses were performed on a BD FACSCanto II (BD Bioscience, Heidelberg, Germany) and analyzed using BD FACSDiva software V8.0.
Western blot
Cell lysis, SDS-PAGE and Western blots were performed as described previously. 31 For pJAK2 analysis cells were lysed directly in 1 £ Laemmli sample buffer. Antibodies used were: pSTAT3 (Tyr705, CS#9131), STAT3 (CS#9132S), STAT4 (clone C46B10, CS#2653), pJAK2 (Tyr1008, D4A8, CS#8082), JAK2 (D2E12, CS#3230), GzmB (CS#4275) and Prf1 (CS#3693) all from Cell Signaling Technology; panERK (clone 16/ERK) and pSTAT4 (Tyr693, clone 38/pSTAT4) from BD Transduction Laboratories. Quantification of Western blots was done with ImageJ software. miRNA analysis RNA was isolated from expanded NK cells or ex vivo DX5 MACS-purified NK cells using miRNeasy Mini Kit (Qiagen). Reverse transcription was performed using miScript II RT Kit (Qiagen) according to manufacturer's instructions. Quantitative PCR was performed on Stratagene MX3000 (Agilent Technology, Boebelingen, Germany) using miScript SYBR Green PCR Kit (Qiagen). Following miScript Primer Assays (Qiagen) were used: Hs_SNORD72_1 as an internal control, Mm_miR-27a*_1, Mm_miR-155_1, Mm_miR-30e_2, Mm_miR-223_2. The qPCR was analyzed using the standard curve method as described previously. 62 Expression levels are shown relative to expression in WT NK cells.
Transcriptional profile analysis RNA was isolated from expanded NK cells using peqGOLD TriFast (PEQLAB) and further purified using RNeasy Mini Kit (Qiagen) according to the manufacturers' instructions. RNA quality was determined by 2100 Bioanalyzer Instrument (Agilent Technologies, Boebelingen, Germany) and only samples with RNA integrity number (RIN) over 8,7 were used for further analysis. The transcriptional profile of WT, Tyk2 K923E and Tyk2 ¡/¡ NK cells in biological triplicates was determined using GeneChip microarray assay (Affymetrix Mouse Gene 2.0 ST arrays). Sample preparation for microarray hybridization was carried out as described in the Affymetrix GeneChip WT PLUS Reagent Kit User Manual (Affymetrix). Sample processing was performed at an Affymetrix Service Provider and Core Facility, "KFB -Center of Excellence for Fluorescent Bioanalytics" (Regensburg, Germany). Data analysis was performed 
NK cell IFNg and CCL3 production
For in vitro expanded NK cells, IFNg production was assessed in the cell culture supernatant using Mouse IFN-gamma Quantikine ELISA (R&D Systems). For ex vivo NK cells, IFNg and CCL3 production was analyzed by flow cytometry as follows: one day prior to the experiment, tubes were C. Splenocytes were seeded at 5 £ 10 6 cells/tube in 400 mL RPMI1640 complete medium. After 1 h of incubation at 37 C, brefeldin A (eBioscience) was added and cells were incubated for another 4 h for IFNg or 7 h for CCL3. Splenocytes were stained for CD3e and DX5 and intracellular IFNg or CCL3 using Foxp3/Transcription Factor Staining Buffer Set according to manufacturer's instructions (eBioscience). The percentage of IFNg C or CCL3 C NK cells was assessed by flow cytometry.
Degranulation assay
Tubes were coated with anti-NK1.1 or anti-Ly49D antibody and splenocytes were seeded as described above. Cells were incubated for 4 h at 37 C in the presence of anti-CD107a antibody. Splenocytes were then stained for CD3e and DX5 and the expression of CD107a on NK cells was analyzed by flow cytometry. The data are presented as a difference between CD107a mean fluorescence intensities (MFI) of anti-NK1.1/anti-Ly49D antibody stimulated and unstimulated sample.
NK cell cytotoxicity assays
In vitro NK cell cytotoxicity assays were performed as previously described 40 using YAC-1, RMA-S and RMA-Rae1 as target cells. In vivo cytotoxicity assays were performed as follows: splenocytes from b2m ¡/¡ and WT mice were isolated and stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) according to the manufacturer's instructions (Molecular Probes, CellTrace TM CFSE Cell Proliferation Kit) at 5 mM and 0.5 mM, respectively. b2m ¡/¡ and WT splenocytes were mixed at a 1:1 ratio and injected intravenously into recipient mice. The input sample was stored at 4 C. After 16 h, spleens of recipient mice were isolated (output samples) and the ratio of CFSE high / CFSE low cells was assessed by flow cytometry. The rejection of b2m ¡/¡ cells was calculated as follows:
Statistical analysis Unpaired t-tests or one-way ANOVA with Bonferroni post tests were performed using GraphPad Prism Ò version 5.00 or 6.00
for Mac (GraphPad Software). The level of significance is indicated for each experiment (*P < 0.05; **P < 0.01; ***P < 0.001).
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